Nivolumab

You have access
Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA and MAREK STASTNY

Anticancer Research April 2022, 42 (4) 1987-1995; DOI: https://doi.org/10.21873/anticanres.15677
You have access
Efficacy of a Flat Low Dose of Nivolumab in Advanced Cancer: A Retrospective Case Series
SOFIE JORIS, CHRISTEL FONTAINE, LORE DECOSTER, JACQUES VANDERAUWERA, KRIS THIELEMANS, WIM WAELPUT and JACQUES DE-GRÈVE

Anticancer Research March 2022, 42 (3) 1433-1437; DOI: https://doi.org/10.21873/anticanres.15613
You have access
Concurrent Nivolumab and Metformin in Diabetic Cancer Patients: Is It Safe and More Active?
CHIARA CICCARESE, ROBERTO IACOVELLI, SEBASTIANO BUTI, FRANCESCA PRIMI, SERENA ASTORE, FRANCESCO MASSARI, MIRIAM GRAZIA FERRARA, GIUSEPPE PALERMO, NAZARIO FOSCHI, VALERIO IACOVELLI, ERNESTO ROSSI, GIOVANNI SCHINZARI, PIERLUIGI BOVE, PIERFRANCESCO BASSI, EMILIO BRIA and GIAMPAOLO TORTORA

Anticancer Research March 2022, 42 (3) 1487-1493; DOI: https://doi.org/10.21873/anticanres.15620
You have access
Prognostic Impact of Immune-related Adverse Events in Gastric Cancer Patients Treated With Nivolumab
HIDEAKI SUEMATSU, KAZUKI KANO, TAKANOBU YAMADA, ITARU HASHIMOTO, HAYATO WATANABE, KOSUKE TAKAHASHI, MAMORU WATANABE, KEI HAYASHI, YOSHIHIRO KANETA, MITSUHIRO FURUTA, YASUHIRO INOKUCHI, NOZOMU MACHIDA, TORU AOYAMA, HIROSHI TAMAGAWA, NORIO YUKAWA, YASUSHI RINO, MUNETAKA MASUDA, TAKASHI OGATA and TAKASHI OSHIMA

Anticancer Research March 2022, 42 (3) 1535-1540; DOI: https://doi.org/10.21873/anticanres.15626
You have access
PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer
TATSUYA ITO, ISAKU OKAMOTO, KUNIHIKO TOKASHIKI, HIROKI SATO, TAKURO OKADA, GAI YAMASHITA, TOSHITAKA NAGAO, HIDEAKI HIRAI, NATSUKI SAIGUSA and KIYOAKI TSUKAHARA

Anticancer Research March 2022, 42 (3) 1547-1554; DOI: https://doi.org/10.21873/anticanres.15628
You have access
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma
TAKURO OKADA, CHIHIRO FUSHIMI, TAKASHI MATSUKI, ISAKU OKAMOTO, HIROKI SATO, TAKAHITO KONDO, KUNIHIKO TOKASHIKI, TAKUMA KISHIDA, TATSUYA ITO, GAI YAMASHITA, YUSUKE AIHARA, KENJI HANYU, YUKIOMI KUSHIHASHI, TATSUO MASUBUCHI, YUICHIRO TADA, KOUKI MIURA, YUKI HARADA, KAHO MOMIYAMA, TAKU YAMASHITA, GO OMURA, HIDEAKI TAKAHASHI, NOBUHIKO ORIDATE and KIYOAKI TSUKAHARA

Anticancer Research March 2022, 42 (3) 1607-1613; DOI: https://doi.org/10.21873/anticanres.15635
You have access
A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma
RENPEI KATO, TAKAHIRO KOJIMA, TOMOKAZU SAZUKA, HAYATO YAMAMOTO, SHOHEI FUKUDA, KAZUTOSHI YAMANA, YUSUKE SUGINO, SHUZO HAMAMOTO, NOBORU NAKAIGAWA, KOKI KABU, HIROSHI MURAKAMI and WATARU OBARA

Anticancer Research December 2021, 41 (12) 6199-6209; DOI: https://doi.org/10.21873/anticanres.15439
You have access
Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
HIROSHI AOKI, NAOKI MATSUMOTO, HIROSHI TAKAHASHI, MASAYUKI HONDA, TOMOHIRO KANEKO, SHUHEI ARIMA, TOMOTAKA ISHII, TAKU MIZUTANI, RYOTA MASUZAKI, KAZUSHIGE NIREI, HIROAKI YAMAGAMI, MASAHIRO OGAWA, TATSUO KANDA, MITSUHIKO MORIYAMA and KATSUHIRO MIURA

Anticancer Research December 2021, 41 (12) 6225-6230; DOI: https://doi.org/10.21873/anticanres.15442
You have access
Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients
YUKIKO SHIMODA, TATSUYA YOSHIDA, MASAYUKI SHIRASAWA, TAKAAKI MIZUNO, HITOMI JO, YUJI MATSUMOTO, YUKI SHINNO, YUSUKE OKUMA, YASUSHI GOTO, HIDEHITO HORINOUCHI, NOBORU YAMAMOTO, YASUSHI YATABE, YUICHIRO OHE and NORIKO MOTOI

Anticancer Research November 2021, 41 (11) 5739-5747; DOI: https://doi.org/10.21873/anticanres.15390
You have access
Real-world Outcomes of Tyrosine Kinase Inhibitors Immediately After Immune Checkpoint Inhibitors in Renal Cell Carcinoma
TAIGO KATO, AKIRA NAGAHARA, NORIHIKO KAWAMURA, WATARU NAKATA, TETSUJI SODA, KYOSUKE MATSUZAKI, KOJI HATANO, ATSUNARI KAWASHIMA, TAKESHI UJIKE, RYOICHI IMAMURA, KENSAKU NISHIMURA, SHINGO TAKADA, MASAO TSUJIHATA, SEIJI YAMAGUCHI, TETSUYA TAKAO, YASUTOMO NAKAI, MASASHI NAKAYAMA, NORIO NONOMURA and MOTOHIDE UEMURA

Anticancer Research November 2021, 41 (11) 5811-5816; DOI: https://doi.org/10.21873/anticanres.15398

Main menu

User menu

Search

Nivolumab

Pages